FERTILO FORTE DENK​ ​POWDER FOR ORAL SUSPENSION

Indications

• Folate-deficient megaloblastic anemia
• Prevention of neural tube defects in pregnancy
• Prevention of methotrexate-induced side effects

Mechanism of action

Folic acid is biochemically inactive until it is converted to tetrahydrofolic acid and methyltetrahydrofolate by dihydrofolate reductase (DHFR). These active forms are taken up by cells via receptor-mediated endocytosis and are essential for normal erythropoiesis, nucleic acid synthesis, amino acid metabolism, and the remethylation of homocysteine to methionine using vitamin B12 as a cofactor. The principal function of folate is to facilitate one-carbon transfer reactions necessary for DNA synthesis and repair.

Pharmacodynamics

As a water-soluble vitamin, folic acid plays a vital role in cell division and growth. It is involved in the biosynthesis of purines and thymidylates, which are necessary for deoxyribonucleic acid (DNA) synthesis. Deficiency in folic acid can lead to impaired thymidylate synthesis, resulting in megaloblastic and macrocytic anemias. Folic acid is particularly critical during rapid cell division phases, such as during infancy and pregnancy, and helps prevent neural tube defects.

Pharmacokinetics

Folic acid is absorbed in the intestines and is transported in the bloodstream primarily as 5-methyltetrahydrofolate. It is actively excreted in urine and can also be found in breast milk. The bioavailability of folic acid is generally high, and dietary sources such as leafy greens, liver, and yeast contribute significantly to folic acid levels in the body. The half-life of folic acid in the body is influenced by dietary intake and physiological needs.

Adverse effects

• Hypersensitivity reactions
• Nausea
• Anorexia
• Abdominal cramps
• Diarrhea

Interactions

• Antiepileptic drugs may increase folate requirement
• Methotrexate may require concurrent folic acid supplementation to prevent side effects

Precautions

• Should not be used in undiagnosed megaloblastic anaemia without concurrent vitamin B12 assessment
• Caution in patients with a history of hypersensitivity to folic acid

Pregnancy

Folic acid is recommended for all women of childbearing potential to prevent neural tube defects, with a typical dose of 400 micrograms daily before conception and until week 12 of pregnancy.

Breast-feeding

Folic acid is actively excreted in breast milk and supplementation is generally safe during breastfeeding.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Tablets
• Oral solution

Dosage

Children: Refer to specific product guidelines for paediatric dosing, as it will vary based on the active ingredient within the hydrate form.

Adults: Refer to specific product guidelines for adult dosing, as it will vary based on the active ingredient within the hydrate form.

Mechanism of action

The specific mechanism of action for 3hydrate depends on the active pharmaceutical ingredient it is associated with. Generally, hydrates may enhance solubility and dissolution rates, which can lead to improved pharmacological effects. For instance, if the hydrate is of an antibiotic, the enhanced solubility may increase the drug's effective concentration in the bloodstream, thus improving its therapeutic efficacy.

Pharmacodynamics

Pharmacodynamics of hydrated forms typically focuses on the relationship between drug concentration and its effect on the body. The presence of water molecules in the crystalline structure can lead to altered interaction with biological targets, potentially enhancing efficacy through improved absorption and bioavailability. The specific effects would vary based on the active drug component.

Pharmacokinetics

Pharmacokinetics of 3hydrate forms generally reflect the drug’s absorption, distribution, metabolism, and excretion (ADME) characteristics. The hydration state can affect the dissolution rate and subsequently the absorption in the gastrointestinal tract. Additionally, the distribution may be influenced by the drug's solubility in bodily fluids, while metabolism and excretion will depend on the properties of the active ingredient.

Pregnancy

Use during pregnancy should be avoided unless clearly needed. Consult healthcare providers for specific advice.

Breast-feeding

Caution is advised when using this drug while breastfeeding. Consult healthcare providers for specific advice.

Storage

Store in a cool, dry place, away from direct sunlight and moisture.

Indications

• Metabolic disorders
• Nutritional deficiencies
• Energy production enhancement
• Support for enzyme activity

Dosage

Children: Refer to specific coenzyme formulations for dosing information, as dosages can vary widely based on intended use and formulation.

Adults: Refer to specific coenzyme formulations for dosing information, as dosages can vary widely based on intended use and formulation.

Mechanism of action

Coenzymes function by binding to enzymes and assisting in the catalytic activity. They may serve as carriers for specific chemical groups or facilitate the transfer of electrons, thereby enhancing the enzyme's ability to convert substrates into products. The specific mechanism can vary depending on the type of coenzyme and the enzyme it interacts with.

Pharmacodynamics

Coenzymes enhance the activity of enzymes by stabilizing transition states, reducing activation energy, and enabling the conversion of substrates into their respective products. They are essential for numerous biological processes, including energy metabolism, amino acid synthesis, and nucleic acid synthesis. The functional impact of coenzymes is largely dependent on their concentration and the presence of specific enzymes.

Pharmacokinetics

The pharmacokinetics of coenzymes can vary widely depending on the specific coenzyme and its role in metabolic pathways. Generally, coenzymes are synthesized in the body from vitamins and other precursor molecules. They are utilized in enzymatic reactions and may be recycled or degraded after use. The absorption, distribution, metabolism, and excretion of coenzymes are influenced by dietary intake and physiological needs.

Pregnancy

Coenzyme Q10 is generally considered safe during pregnancy, but it is advisable to consult a healthcare provider before use.

Breast-feeding

Coenzyme Q10 is likely safe during breastfeeding, but it is recommended to consult a healthcare professional prior to use.

Storage

Store in a cool, dry place away from direct light.

Indications

• Cardiovascular diseases
• Erectile dysfunction
• Peripheral arterial disease
• Wound healing
• Muscle growth and recovery
• Immune system support

Dosage

Children: For paediatric dosing, it is important to refer to the BNF for Children for appropriate guidelines based on the child's age, weight, and clinical condition.

Adults: The typical dosage for adults varies based on the condition being treated, but common oral doses range from 2 to 30 grams per day, divided into multiple doses. For specific dosing recommendations, please refer to the BNF.

Mechanism of action

L-arginine is converted to nitric oxide by nitric oxide synthase (NOS), which is crucial for vascular function and blood flow regulation. NO activates guanylate cyclase, leading to increased levels of cyclic GMP, a secondary messenger that mediates vasodilation and other cellular responses. This pathway is vital in both the cardiovascular and immune systems, with different isoforms of NOS (eNOS, nNOS, iNOS) contributing to various physiological effects.

Pharmacodynamics

L-arginine has been shown to enhance immune responses, improve wound healing, stimulate growth hormone release, and support muscle hypertrophy and tissue repair. Its role in nitric oxide production aids in vasodilation, improving blood circulation and oxygen delivery to tissues, which is essential for recovery and regeneration.

Pharmacokinetics

L-arginine is absorbed from the gastrointestinal tract, with peak plasma concentrations occurring within 1-2 hours after oral administration. It is metabolized primarily in the liver and kidneys, with a half-life of approximately 1-2 hours. The bioavailability of L-arginine can be influenced by dietary intake and metabolic conditions.

Adverse effects

• Gastrointestinal disturbances
• Nausea
• Diarrhea
• Abdominal pain
• Hypotension
• Allergic reactions

Interactions

• Antihypertensive agents may have additive effects leading to increased hypotension
• Sildenafil and other medications for erectile dysfunction may have enhanced effects when used with L-arginine

Precautions

• Caution in patients with a history of asthma or allergies
• Use with caution in patients with hypotension
• Monitor blood pressure in patients taking antihypertensive medications

Pregnancy

The safety of L-arginine in pregnancy has not been established. Consult a healthcare provider before use.

Breast-feeding

L-arginine is excreted in breast milk, and its safety during breastfeeding is not well established. Consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral tablets
• Powder for oral solution
• Capsules

Mechanism of action

Levocarnitine acts as a carrier molecule for long-chain fatty acids, transporting them into mitochondria for beta-oxidation, which is critical for energy production. It also exports acyl groups from subcellular organelles and cells to urine, preventing toxic accumulation. The mechanism of action includes interactions with carnitine transporters, translocases, and acetyltransferases. Additionally, it normalizes the brain's redox state and enhances urea synthesis in the liver, potentially activating the glucocorticoid receptor. L-carnitine's antagonistic effects on thyroid hormone action, including inhibiting its nuclear entry, contribute to its therapeutic applications.

Pharmacodynamics

Levocarnitine plays a significant role in lipid metabolism and energy production through its involvement in the transport of fatty acids into the mitochondria. A deficiency in carnitine can lead to various metabolic issues, including liver, heart, and muscle dysfunction. The therapeutic use of levocarnitine includes its ability to stimulate gastric and pancreatic secretions and treat hyperlipoproteinemias. The L-isomer of carnitine is specifically active in lipid metabolism, and its deficiency can be identified through biochemical markers such as low plasma concentrations of free carnitine and elevated acylcarnitine levels.

Pharmacokinetics

Levocarnitine is absorbed in the intestines and distributed throughout the body tissues. It is primarily metabolized in the liver, with excretion occurring via urine. The pharmacokinetics of levocarnitine can vary based on dietary intake, physiological status, and specific health conditions that may affect its metabolism and clearance. The bioavailability of levocarnitine may also be

Adverse effects

• Nausea
• Vomiting
• Abdominal cramps
• Diarrhea
• Fishy body odor
• Rash
• Seizures (rare)

Interactions

• Anticoagulants may have altered effects.
• Thyroid hormones may have altered action due to L-carnitine's peripheral antagonism.

Precautions

• Use with caution in patients with renal impairment.
• Monitor for potential interactions with other medications.

Pregnancy

Limited data is available on the use of levocarnitine during pregnancy. Use only if clearly needed and after assessing benefits versus risks.

Breast-feeding

Levocarnitine is excreted in human milk. Caution is advised when administered to nursing mothers.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Formulations

• Oral solution
• Tablets
• Capsules

Indications

• Selenium deficiency
• Cognitive decline
• Cancer (as an adjunct therapy)
• Thyroid disorders

Dosage

Children: Refer to pediatric dosing guidelines or literature for appropriate dosing, as no standardized dose is provided.

Adults: Refer to specific clinical guidelines or literature for dosing recommendations, as no standardized dose is provided.

Mechanism of action

Sodium selenate acts as an essential component of selenoproteins, which are involved in antioxidant defense and redox signaling. It enhances the activity of enzymes such as glutathione peroxidases, which protect cells from oxidative damage. Additionally, sodium selenate has been shown to induce apoptosis in cancer cells through the activation of specific signaling pathways and regulation of gene expression related to cell survival.

Pharmacodynamics

The pharmacodynamic effects of sodium selenate are largely attributed to its role in the synthesis of selenoproteins. These proteins play vital roles in reducing oxidative stress, modulating inflammation, and regulating thyroid hormone metabolism. The antioxidant properties of sodium selenate contribute to its protective effects against cellular damage, while its ability to influence cell signaling pathways can impact cellular proliferation and apoptosis, especially in cancer biology.

Pharmacokinetics

Sodium selenate is absorbed in the gastrointestinal tract following oral administration. The bioavailability of selenium varies depending on dietary sources and the chemical form. Once absorbed, selenium is widely distributed throughout the body, with significant accumulation in the liver, kidneys, and other tissues. It is metabolized primarily in the liver, where it is incorporated into selenoproteins or converted to other forms of selenium. Excretion occurs mainly through urine, with a smaller amount eliminated in feces.

Adverse effects

• Gastrointestinal disturbances
• Fatigue
• Headache
• Skin rash
• Nausea and vomiting
• Selenium toxicity (including symptoms such as garlic-like odor on breath, metallic taste, and neurological symptoms)

Precautions

• Use with caution in patients with known hypersensitivity to selenium compounds
• Monitor selenium levels to avoid toxicity, particularly in patients with renal impairment

Pregnancy

The safety of sodium selenate in pregnancy has not been established. Use only if clearly needed and the benefits outweigh the risks.

Breast-feeding

Sodium selenate is excreted in breast milk; caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place, away from light. Keep out of reach of children.

Formulations

• Oral tablets
• Injectable solutions

Indications

• Prevention of vitamin E deficiency
• Antioxidant therapy
• Support in conditions related to oxidative stress

Dosage

Children: Refer to BNF for Children for specific dosage guidelines.

Adults: Refer to BNF for specific dosage guidelines.

Mechanism of action

Tocopherol acts as a radical scavenger, primarily functioning as an antioxidant for lipid bilayers. It donates hydrogen atoms to free radicals, trapping them and preventing cellular damage. Its effectiveness is influenced by its location within the membrane and its interaction with cytosolic reductants like ascorbate. Tocopherol can trap multiple radicals, including alkyl and peroxy radicals.

Pharmacodynamics

The antioxidant properties of tocopherol lead to significant pharmacodynamic effects, including the inhibition of cell death through modulation of protein kinase C (PKC). Tocopherol also exhibits anti-inflammatory effects, which can be attributed to its influence on cytokines, prostaglandins, prostanoids, and thromboxanes. These interactions may contribute to its protective effects in various pathological conditions.

Pharmacokinetics

Tocopherol is absorbed in the intestines and its bioavailability can be influenced by dietary fat intake. It is transported in the plasma primarily bound to lipoproteins. Tocopherol is stored in adipose tissue and the liver, and its elimination occurs through bile and urine. The half-life of tocopherol can vary depending on the individual's nutritional status and other factors.

Pregnancy

Tocopherol is generally considered safe during pregnancy, but it is advisable to consult a healthcare provider before use.

Breast-feeding

Tocopherol is excreted in breast milk, and while it is considered safe, a healthcare provider should be consulted for specific recommendations.

Storage

Store in a cool, dry place away from direct sunlight.

Mechanism of action

Folic acid, as it is biochemically inactive, is converted to tetrahydrofolic acid and methyltetrahydrofolate by dihydrofolate reductase (DHFR). These folic acid congeners are transported across cells by receptor-mediated endocytosis where they are needed to maintain normal erythropoiesis, synthesize purine and thymidylate nucleic acids, interconvert amino acids, methylate tRNA, and generate and use formate. Using vitamin B12 as a cofactor, folic acid can normalize high homocysteine levels by remethylation of homocysteine to methionine via methionine synthetase. Folic acid, after conversion to tetrahydrofolic acid, is necessary for normal erythropoiesis, synthesis of purine and thymidylates, metabolism of amino acids such as glycine and methionine, and the metabolism of histidine. The principal biochemical function of folates is the mediation of one-carbon transfer reactions. 5-Methyltetrahydrofolate donates a methyl group to homocystine, in the conversion of homocystine to L-methionine. ... 5,10-Methyltetrahydrofolate is regenerated from tetrahydrofolate via the enzyme serine hydroxymethyltransferase, a reaction, which in addition to producing 5,10-methyltetrahydrofolate, yields glycine. ... 5,10-methyltetrahydrofolate, supplies the one carbon group for the methylation of deoxyuridylic acid to form the DNA precursor thymidylic acid. This reaction is catalyzed by thymidylate synthase and the folate product of the reaction is dihydrofolate. Dihydrofolate is converted to tetrahydrofolate via the enzyme dihydrofolate reductase ...

Pharmacodynamics

Folic acid is a water-soluble B-complex vitamin found in foods such as liver, kidney, yeast, and leafy, green vegetables. Also known as folate or Vitamin B9, folic acid is an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic acid is the precursor of tetrahydrofolic acid, which is involved as a cofactor for transformylation reactions in the biosynthesis of purines and thymidylates of nucleic acids. Impairment of thymidylate synthesis in patients with folic acid deficiency is thought to account for the defective deoxyribonucleic acid (DNA) synthesis that leads to megaloblast formation and megaloblastic and macrocytic anemias. Folic acid is particularly important during phases of rapid cell division, such as infancy, pregnancy, and erythropoiesis, and plays a protective factor in the development of cancer. As humans are unable to synthesize folic acid endogenously, diet and supplementation is necessary to prevent deficiencies. In order to function properly within the body, folic acid must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted by anti-metabolite therapies such as [DB00563] as they function as DHFR inhibitors to prevent DNA synthesis in rapidly dividing cells, and therefore prevent the formation of DHF and THF. In general, folate serum levels below 5 ng/mL indicate folate deficiency, and levels below 2 ng/mL usually result in megaloblastic anemia.

Mechanism of action

Many of supplemental L-arginine's activities, including its possible anti-atherogenic actions, may be accounted for by its role as the precursor to nitric oxide or NO. NO is produced by all tissues of the body and plays very important roles in the cardiovascular system, immune system and nervous system. NO is formed from L-arginine via the enzyme nitric oxide synthase or synthetase (NOS), and the effects of NO are mainly mediated by 3,'5' -cyclic guanylate or cyclic GMP. NO activates the enzyme guanylate cyclase, which catalyzes the synthesis of cyclic GMP from guanosine triphosphate or GTP. Cyclic GMP is converted to guanylic acid via the enzyme cyclic GMP phosphodiesterase. NOS is a heme-containing enzyme with some sequences similar to cytochrome P-450 reductase. Several isoforms of NOS exist, two of which are constitutive and one of which is inducible by immunological stimuli. The constitutive NOS found in the vascular endothelium is designated eNOS and that present in the brain, spinal cord and peripheral nervous system is designated nNOS. The form of NOS induced by immunological or inflammatory stimuli is known as iNOS. iNOS may be expressed constitutively in select tissues such as lung epithelium. All the nitric oxide synthases use NADPH (reduced nicotinamide adenine dinucleotide phosphate) and oxygen (O2) as cosubstrates, as well as the cofactors FAD (flavin adenine dinucleotide), FMN (flavin mononucleotide), tetrahydrobiopterin and heme. Interestingly, ascorbic acid appears to enhance NOS activity by increasing intracellular tetrahydrobiopterin. eNOS and nNOS synthesize NO in response to an increased concentration of calcium ions or in some cases in response to calcium-independent stimuli, such as shear stress. In vitro studies of NOS indicate that the Km of the enzyme for L-arginine is in the micromolar range. The concentration of L-arginine in endothelial cells, as well as in other cells, and in plasma is in the millimolar range. What this means is that, under physiological conditions, NOS is saturated with its L-arginine substrate. In other words, L-arginine would not be expected to be rate-limiting for the enzyme, and it would not appear that supraphysiological levels of L-arginine which could occur with oral supplementation of the amino acid^would make any difference with regard to NO production. The reaction would appear to have reached its maximum level. However, in vivo studies have demonstrated that, under certain conditions, e.g. hypercholesterolemia, supplemental L-arginine could enhance endothelial-dependent vasodilation and NO production.

Pharmacodynamics

Studies have shown that is has improved immune responses to bacteria, viruses and tumor cells; promotes wound healing and regeneration of the liver; causes the release of growth hormones; considered crucial for optimal muscle growth and tissue repair.

Mechanism of action

Levocarnitine can be synthesised within the body from the amino acids lysine or methionine. Vitamin C (ascorbic acid) is essential to the synthesis of carnitine. Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. Levocarnitine is handled by several proteins in different pathways including carnitine transporters, carnitine translocases, carnitine acetyltransferases and carnitine palmitoyltransferases. L-Carnitine is a peripheral antagonist of thyroid hormone action in some tissues. It inhibits thyroid hormone entry into cell nuclei. In a controlled clinical trial, L-carnitine was shown to reverse or prevent some symptoms of hyperthyroidism. ... Mortality and metabolic consequences of acute ammonium intoxication in mice are reduced by pharmacologic admin of L-carnitine. The mechanism for this effect may have 2 components. L-Carnitine admin normalizes the redox state of the brain (perhaps by incr the avail of beta-hydroxybutyrate and/or acetyl-L-carnitine to the brain), and it incr the rate of urea synth in the liver, perhaps in part by activation of the glucocorticoid receptor. At least part of the protective effect is associated with flux through the carnitine acyltransferases, as analogs of L-carnitine that are competitive inhibitors of carnitine acyltransferases enhance the toxicity of acute ammonium admin. Thus, it has been proposed that L-carnitine incr urea synth in the liver by facilitating fatty acid entry into mitochondria, leading to incr flux through the beta-oxidation pathway, an incr of intramitochondrial reducing equivalents, and enhancement of ATP production. ... Levocarnitine is necessary for normal mammalian fat utilization and energy metabolism. It facilitates entry of long-chain fatty acids into cellular mitochondria, where they are used during oxidation and energy production. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Carnitine's primary mechanism of action is apparently attributable to its role as a cofactor in the transformation of free long-chain fatty acids into acylcarnitines for subsequent transport into the mitochondrial matrix. Carnitine is involved in the metabolism of ketones for energy and the conversion of branched-chain amino acids - valine, leucine, and isoleucine - into energy. /Carnitine/ L-Carnitine participates in a reversible transesterification reaction, in which an acyl group is transferred from coenzyme A to the hydroxyl group of L-carnitine ... /This reaction facilitates the/ transfer of long-chain fatty acids from cytoplasm ... /and/ chain-shortened /very-long-chain/ fatty acids from peroxisomes to mitochondria /and the/ modulation of the acyl-CoA/CoA ratio in cellular compartments.

Pharmacodynamics

Levocarnitine is a carrier molecule in the transport of long chain fatty acids across the inner mitochondrial membrane. It also exports acyl groups from subcellular organelles and from cells to urine before they accumulate to toxic concentrations. Lack of carnitine can lead to liver, heart, and muscle problems. Carnitine deficiency is defined biochemically as abnormally low plasma concentrations of free carnitine, less than 20 µmol/L at one week post term and may be associated with low tissue and/or urine concentrations. Further, this condition may be associated with a plasma concentration ratio of acylcarnitine/levocarnitine greater than 0.4 or abnormally elevated concentrations of acylcarnitine in the urine. Only the L isomer of carnitine (sometimes called vitamin BT) affects lipid metabolism. The "vitamin BT" form actually contains D,L-carnitine, which competitively inhibits levocarnitine and can cause deficiency. Levocarnitine can be used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias.

Mechanism of action

Tocopherol acts as a radical scavenger. It mainly acts as an antioxidant for lipid bilayers. Tocopherol's functions depend on the H-atom donating ability, location, and movement within the membrane, as well as the efficiency in the radical recycling by some cytosolic reductants such as ascorbate. Tocopherol actions are related to the trap of radicals, and it has been shown that even in the absence of substituents in the ortho-positions, tocopherol can trap more than two radicals. The type of radicals available for tocopherol are alkyl and peroxy.

Pharmacodynamics

The antioxidant effects of tocopherol can be translated into different changes at the pharmacodynamic level. In vitro studies have shown that this antioxidant activity can produce modification in protein kinase C (PKC) which will later be translated into an inhibition of cell death. Some other derivate effects are the anti-inflammatory properties of tocopherol which can be related to the modulation of cytokines or prostaglandins, prostanoids and thromboxanes.